Basal ganglia components connection functions Pathophysiology of Parkinsonism clinical features and treatment 15 marks mbbs answer 1st year

Reading File
Finding Sources
Finding Sources
Searching PubMed

"Parkinson disease"[MeSH Terms] AND treatment

Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

basal ganglia direct and indirect pathway diagram substantia nigra thalamus

This dual-panel image provides an anatomical and histological overview of the basal ganglia and nigrostriatal systems. Panel A is a color-coded anatomical diagram of a coronal brain section illustrating basal ganglia circuitry. It depicts the direct pathway (red arrows), indirect pathway (black arrows), and dopaminergic (DA) projections (green arrows). Key labeled structures include the Caudate nucleus (Cd), Putamen (Pt), Thalamus (Th), Subthalamic Nucleus (STN), Globus Pallidus external (GPe) and internal (GPi) segments, Substantia Nigra pars compacta (SNc), Substantia Nigra reticulata (SNr), and Ventral Tegmental Area (VTA). Panel B is a coronal histological photograph of a monkey brain using Dopamine Transporter (DAT) immunostaining. The image shows intense white signal in the striatum (caudate and putamen) and the SNc, indicating high density of dopamine innervation compared to the darker surrounding cortical and thalamic tissue. This material is pedagogically significant for understanding Parkinson’s disease pathophysiology and the anatomical organization of motor control circuits.

This dual-panel image provides an anatomical and histological overview of the basal ganglia and nigrostriatal systems. Panel A is a color-coded anatomical diagram of a coronal brain section illustrating basal ganglia circuitry. It depicts the direct pathway (red arrows), indirect pathway (black arrows), and dopaminergic (DA) projections (green arrows). Key labeled structures include the Caudate nucleus (Cd), Putamen (Pt), Thalamus (Th), Subthalamic Nucleus (STN), Globus Pallidus external (GPe) and internal (GPi) segments, Substantia Nigra pars compacta (SNc), Substantia Nigra reticulata (SNr), and Ventral Tegmental Area (VTA). Panel B is a coronal histological photograph of a monkey brain using Dopamine Transporter (DAT) immunostaining. The image shows intense white signal in the striatum (caudate and putamen) and the SNc, indicating high density of dopamine innervation compared to the darker surrounding cortical and thalamic tissue. This material is pedagogically significant for understanding Parkinson’s disease pathophysiology and the anatomical organization of motor control circuits.

This medical illustration presents a coronally sectioned schematic of the human brain, specifically detailing the functional neuroanatomy and pathways of the basal ganglia. The diagram categorizes the striatum (STR) into the dorsal striatum (DS) and ventral striatum (VS), the latter including the nucleus accumbens. Key subcortical structures identified include the Thalamus (Th), Globus Pallidus external (GPe) and internal (GPi) segments, Subthalamic Nucleus (STN), Hippocampus (HC), Substantia Nigra pars compacta (SNc), Substantia Nigra pars reticulata (SNr), and the Ventral Tegmental Area (VTA). The primary focus is the visual differentiation of motor and cognitive circuits via the direct and indirect pathways. Green arrows represent the direct pathway, illustrating excitatory projections that facilitate movement or cognitive gating, while red arrows denote the indirect pathway, representing inhibitory circuits. Dopaminergic modulation is highlighted by labeling D1 (excitatory) and D2 (inhibitory) receptors within the striatum, showing projections from the midbrain (VTA/SNc). This anatomical model is essential for understanding movement disorders like Parkinson’s disease and cognitive processes involving reward and habituation.

This medical illustration presents a coronally sectioned schematic of the human brain, specifically detailing the functional neuroanatomy and pathways of the basal ganglia. The diagram categorizes the striatum (STR) into the dorsal striatum (DS) and ventral striatum (VS), the latter including the nucleus accumbens. Key subcortical structures identified include the Thalamus (Th), Globus Pallidus external (GPe) and internal (GPi) segments, Subthalamic Nucleus (STN), Hippocampus (HC), Substantia Nigra pars compacta (SNc), Substantia Nigra pars reticulata (SNr), and the Ventral Tegmental Area (VTA). The primary focus is the visual differentiation of motor and cognitive circuits via the direct and indirect pathways. Green arrows represent the direct pathway, illustrating excitatory projections that facilitate movement or cognitive gating, while red arrows denote the indirect pathway, representing inhibitory circuits. Dopaminergic modulation is highlighted by labeling D1 (excitatory) and D2 (inhibitory) receptors within the striatum, showing projections from the midbrain (VTA/SNc). This anatomical model is essential for understanding movement disorders like Parkinson’s disease and cognitive processes involving reward and habituation.

This pathophysiology diagram illustrates a hypothetical model of basal ganglia circuitry and the neurobiological effects of amphetamine-type stimulants (ATS). The top panel shows the normal state, detailing the balance between direct and indirect pathways. Key structures include the cortex, striatum (D1/D2 receptors), globus pallidus external (GPe) and internal (GPi), subthalamic nucleus (STN), substantia nigra pars compacta (SNc) and reticulata (SNr), and the thalamus. Neurotransmitter flow is color-coded: green for glutamate (excitatory), blue for GABA (inhibitory), and red for dopamine (DA). The bottom panel depicts the ATS-altered state, showing pathologically thickened lines representing enhanced dopaminergic and glutamatergic signaling. A detailed inset focuses on the striatal microenvironment, highlighting how ATS disturb the inhibitory influence of GABA interneurons on GABA projection neurons. This disruption leads to over-activation of the direct pathway and inhibition of the indirect pathway, ultimately resulting in increased glutamate release from the thalamus to the cortex. This model explains the polysynaptic mechanisms underlying ATS use disorders and neurotoxicity.

This pathophysiology diagram illustrates a hypothetical model of basal ganglia circuitry and the neurobiological effects of amphetamine-type stimulants (ATS). The top panel shows the normal state, detailing the balance between direct and indirect pathways. Key structures include the cortex, striatum (D1/D2 receptors), globus pallidus external (GPe) and internal (GPi), subthalamic nucleus (STN), substantia nigra pars compacta (SNc) and reticulata (SNr), and the thalamus. Neurotransmitter flow is color-coded: green for glutamate (excitatory), blue for GABA (inhibitory), and red for dopamine (DA). The bottom panel depicts the ATS-altered state, showing pathologically thickened lines representing enhanced dopaminergic and glutamatergic signaling. A detailed inset focuses on the striatal microenvironment, highlighting how ATS disturb the inhibitory influence of GABA interneurons on GABA projection neurons. This disruption leads to over-activation of the direct pathway and inhibition of the indirect pathway, ultimately resulting in increased glutamate release from the thalamus to the cortex. This model explains the polysynaptic mechanisms underlying ATS use disorders and neurotoxicity.

This medical illustration presents a pathophysiology diagram of the human brain in coronal section, focusing on the motor circuitry of the basal ganglia. The diagram maps the structural and functional relationships between the cerebral cortex, striatum (caudate nucleus and putamen), globus pallidus externa (GPe), globus pallidus interna (GPi), subthalamic nucleus (STN), substantia nigra (SN), and thalamus. Three primary signaling pathways are color-coded: the Direct Pathway (red), which facilitates movement; the Indirect Pathway (blue), which inhibits movement; and the Hyperdirect Pathway (green). The visual also utilizes distinct arrowheads to indicate neurotransmitter types: pointed arrows represent excitatory glutamatergic projections (e.g., from the cortex and STN), while T-shaped bars represent inhibitory GABAergic projections (e.g., from the striatum and globus pallidus). This anatomical model is essential for understanding neurodegenerative movement disorders such as Huntington’s Disease and Parkinsonism, specifically how striatal degeneration alters cortical excitation and inhibition loops.

This medical illustration presents a pathophysiology diagram of the human brain in coronal section, focusing on the motor circuitry of the basal ganglia. The diagram maps the structural and functional relationships between the cerebral cortex, striatum (caudate nucleus and putamen), globus pallidus externa (GPe), globus pallidus interna (GPi), subthalamic nucleus (STN), substantia nigra (SN), and thalamus. Three primary signaling pathways are color-coded: the Direct Pathway (red), which facilitates movement; the Indirect Pathway (blue), which inhibits movement; and the Hyperdirect Pathway (green). The visual also utilizes distinct arrowheads to indicate neurotransmitter types: pointed arrows represent excitatory glutamatergic projections (e.g., from the cortex and STN), while T-shaped bars represent inhibitory GABAergic projections (e.g., from the striatum and globus pallidus). This anatomical model is essential for understanding neurodegenerative movement disorders such as Huntington’s Disease and Parkinsonism, specifically how striatal degeneration alters cortical excitation and inhibition loops.

Basal Ganglia and Parkinsonism — 15 Marks

A. BASAL GANGLIA

1. Components (Anatomical Parts)

The basal ganglia are paired subcortical nuclei of the telencephalon and diencephalon concerned with motor control:
StructureSub-parts
Corpus striatumCaudate nucleus + Putamen (= Neostriatum/Striatum)
Lenticular nucleusPutamen + Globus pallidus (external segment - GPe, internal segment - GPi)
Subthalamic nucleus (STN)in diencephalon
Substantia nigrapars compacta (SNpc - dopaminergic) and pars reticulata (SNpr - GABAergic)
Amygdalaoften included functionally (limbic component)
About 95% of striatal neurons are GABAergic medium spiny neurons (the output/projection neurons); the rest are cholinergic and GABAergic interneurons - Ganong's Review of Medical Physiology, p. 3694.

2. Connections (Circuitry)

Input: Almost all cerebral cortex (especially motor cortex) sends excitatory glutamatergic fibers to the striatum (caudate + putamen) - the main input nucleus.
Output: GPi and SNpr are the output nuclei, sending inhibitory (GABA) fibers to the thalamus (VA/VL nuclei), which in turn sends excitatory glutamatergic fibers back to the motor cortex - Costanzo Physiology, p. 3465.
Two parallel striato-pallidal circuits regulate this cortico-striato-thalamo-cortical loop:
  • Direct pathway: Striatum ⊣(GABA) GPi/SNpr ⊣(GABA) Thalamus → Cortex. Net effect: disinhibits thalamus → excites motor cortex → facilitates movement.
  • Indirect pathway: Striatum ⊣(GABA) GPe ⊣(GABA) STN →(glutamate, excitatory) GPi/SNpr ⊣(GABA) Thalamus → Cortex. Net effect: has an extra inhibitory relay → inhibits thalamus → suppresses movement.
Dopaminergic modulation: The SNpc sends a nigrostriatal dopaminergic projection back to the striatum. Striatal neurons of the direct pathway carry D1 receptors (dopamine excites them → facilitates the direct/"go" pathway), while neurons of the indirect pathway carry D2 receptors (dopamine inhibits them → suppresses the indirect/"stop" pathway). Thus dopamine normally facilitates movement by simultaneously activating the direct pathway and inhibiting the indirect pathway - Costanzo Physiology, p. 3465-3473; Ganong's Review of Medical Physiology, p. 3694-3712.
Basal ganglia direct and indirect pathway circuitry

3. Functions

  • Planning and smooth execution of voluntary movement (working with the cortex and cerebellum)
  • Regulation of muscle tone and posture
  • Suppression of unwanted/competing movements
  • Contribution to cognitive functions (procedural learning, working memory) and affective/limbic functions (via ventral striatum - nucleus accumbens)
  • Contains no direct connection to lower motor neurons; it acts entirely by modulating cortical output through the thalamus.

B. PARKINSONISM

1. Definition

Parkinsonism is a clinical syndrome of bradykinesia plus at least one of rest tremor or rigidity (with postural instability), of which idiopathic Parkinson's disease (PD) is the commonest cause - Bradley and Daroff's Neurology in Clinical Practice, p. 2314.

2. Pathophysiology

  • Core lesion: progressive degeneration of dopaminergic neurons of the substantia nigra pars compacta, with loss of the nigrostriatal dopamine pathway. Motor symptoms appear once striatal dopamine falls by ~60-80%.
  • Pathological hallmark: intracytoplasmic inclusions called Lewy bodies, composed of aggregated α-synuclein; PD is now regarded as a synucleinopathy. Braak staging shows pathology beginning in the olfactory bulb/medulla (stage 1-2, causing pre-motor hyposmia, constipation, REM sleep behaviour disorder), reaching the substantia nigra at stage 3 (onset of motor features), and later the cortex (stages 5-6, causing dementia) - Katzung's Basic and Clinical Pharmacology, p. 282-297.
  • Etiology: mostly idiopathic; genetic forms involve SNCA (α-synuclein), PARK2 (parkin), LRRK2, PINK1 genes; secondary causes include drugs (dopamine receptor blockers/antipsychotics), toxins (MPTP, manganese, CO), post-encephalitic states, and vascular (multi-infarct) parkinsonism.
  • Circuit consequence of dopamine loss: Loss of nigrostriatal dopamine removes the normal facilitation of the direct pathway (D1) and disinhibition of the indirect pathway (D2). Net result:
  • Indirect pathway becomes overactive → excessive inhibition of thalamus.
  • Direct pathway becomes underactive → reduced facilitation of thalamus.
  • Both changes converge to excessively inhibit the thalamocortical projection, reducing excitatory drive to the motor cortex → bradykinesia/akinesia and rigidity.
  • There is also a relative cholinergic excess in the striatum (since dopamine normally restrains striatal cholinergic interneurons), contributing to tremor and rigidity - hence anticholinergic drugs help.

3. Clinical Features

Cardinal features, remembered as TRAP:
  1. Tremor - 4-6 Hz "pill-rolling" rest tremor, decreases with voluntary movement
  2. Rigidity - "lead-pipe" or "cogwheel" rigidity
  3. Akinesia/Bradykinesia - slowness in initiation and execution of movement, micrographia, hypomimia (masked facies), hypophonia
  4. Postural instability - stooped/flexed posture, shuffling festinant gait, loss of postural reflexes, freezing episodes
Other associated features:
  • Asymmetrical onset
  • Reduced arm swing while walking
  • Non-motor features: anosmia, constipation, REM sleep behaviour disorder, depression/anxiety, autonomic dysfunction (orthostatic hypotension, sialorrhea, sphincter disturbance), cognitive decline/dementia in advanced disease - Bradley and Daroff's Neurology in Clinical Practice, p. 2323-2424; Katzung's Basic and Clinical Pharmacology, p. 282.

4. Treatment

Pharmacological (aimed at restoring dopaminergic/cholinergic balance):
Drug classExampleMechanism/Notes
Dopamine precursorLevodopa + carbidopa (carbidopa = peripheral decarboxylase inhibitor, prevents peripheral conversion/side effects, allows more L-dopa to cross BBB)Most effective; crosses BBB via LAT transporter, converted to dopamine in brain. Long-term use → motor fluctuations ("wearing-off," "on-off") and dyskinesias
Dopamine agonistsPramipexole, Ropinirole, Bromocriptine, RotigotineDirectly stimulate D2 (and D1/D3) receptors; useful early, especially in younger patients to delay levodopa-related dyskinesia
MAO-B inhibitorsSelegiline, RasagilineBlock dopamine breakdown, mild symptomatic benefit, possible neuroprotection
COMT inhibitorsEntacapone, TolcaponePrevent peripheral breakdown of levodopa, prolong its action, used as adjunct in fluctuations
AnticholinergicsTrihexyphenidyl, BenzhexolCorrect relative cholinergic excess; useful mainly for tremor in younger patients; avoid in elderly (cognitive side effects)
Amantadine-Weak NMDA antagonist and increases dopamine release; helps dyskinesias and mild symptoms
Non-pharmacological/Surgical:
  • Deep Brain Stimulation (DBS) of subthalamic nucleus or GPi - for advanced disease with motor fluctuations refractory to medical therapy, or disabling tremor
  • Physiotherapy, speech therapy, occupational therapy, and exercise programs
  • Supportive care for non-motor symptoms (antidepressants, management of autonomic dysfunction)
  • Katzung's Basic and Clinical Pharmacology, p. 299-322.
Recent evidence note: A 2025 German Society of Neurology-based systematic review on invasive therapies for PD (PMID: 39985674) reinforces DBS as standard for advanced, fluctuating PD; a 2025 systematic review (PMID: 41247590) discusses evolving management of nocturnal hypokinesia/early-morning "off" states, which may refine adjunct drug timing beyond older textbook protocols. These don't contradict the core pathophysiology/treatment framework above, but reflect ongoing refinement of advanced-therapy indications.

Summary Diagram for Answer

Draw: Cortex → Striatum → (Direct: GPi/SNpr → Thalamus → Cortex) and (Indirect: GPe → STN → GPi/SNpr → Thalamus → Cortex), with SNpc-striatum dopamine loop shown feeding both pathways. Mark the site of dopaminergic neuron loss in PD at SNpc with a cross, and show consequent net inhibition of thalamocortical output.
This is a shared conversation. Sign in to Orris to start your own chat.